Draco Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 0.20 M
- Company Age 13 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 9344.25%
- Profit Growth 278.61%
- Ebitda 564.78%
- Net Worth 338.03%
- Total Assets 0.77%
About Draco Lifesciences
Draco Lifesciences Private Limited (DLPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 September 2011 and has a history of 13 years and five months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Vijay Dave, Kamal Patcha, and Bhavesh Shah serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233MH2011PTC222207
- Company No.
222207
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Sep 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Draco Lifesciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Dave  | Director | 21-Sep-2011 | Current |
| Kamal Patcha | Director | 21-Sep-2011 | Current |
| Bhavesh Shah | Director | 21-Sep-2011 | Current |
Financial Performance of Draco Lifesciences.
Draco Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 9344.25% increase. The company also saw a substantial improvement in profitability, with a 278.61% increase in profit. The company's net worth Soared by an impressive increase of 338.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Draco Lifesciences?
In 2023, Draco Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Unicorn Pharmachem Private LimitedVijay Dave, Kamal Patcha and 1 more are mutual person
Harikamal Exim Logistics Private LimitedKamal Patcha is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Draco Lifesciences?
Unlock and access historical data on people associated with Draco Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Draco Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Draco Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
